Accelerate Rational Vector Selection & Engineering to Improve Targeting, Limit Immunogenicity, Lower Doses, & Reduce Cost of Goods

Welcome to the 5th Next Generation Gene Therapy Vectors Summit!

Achieve Safety through Novel Capsids & Payloads

2024 saw huge investments in gene therapy vectors. Following a $1.1 billion acquisition of Kate Therapeutics by Novartis and a collaboration between Roche and Dyno Therapeutics, which could generate more than $1 billion for Dyno, it’s time to come together and continue unlocking the ever-clearer potential of vector therapies.

The 5th Next Generation Gene Therapy Vectors Summit returns as the only vector therapy-specific platform for experts to join forces, share technical insights, transform viral and non-viral vector design and selection, and streamline translation to the clinic.

Providing an unmatched, close-knit collaborative environment created specifically with and for the gene therapy vector community, connect and learn from leaders such as Spark Therapeutics, Novartis, 4D Molecular Therapeutics, Apertura Gene Therapy, and Coave Therapeutics, in a bid to discover innovative, rational vector design and AI-driven approaches. Emphasize cost- and time-effective strategies for non-clinical testing and vector manufacturing to achieve clinical validation and deliver vector therapies to more patient populations.

5th Next Generation Gene Therapy Vectors Summit

Quick Download the Brochure Here to Explore:

10+

New Companies Speaking

20+

Expert Speakers

40+

Companies Represented

60+

Attendees to Network With

Jorge

I am looking forward to the Next Generation Gene Therapy Vectors Summit because it creates space for cross-functional collaboration on one of the field’s most urgent challenges - developing safe and effective vectors with efficiency. This meeting is a chance to share how regulatory approaches, capsid engineering, and translational strategies can work together to accelerate therapies for patients

Jorge Santiago-Ortiz PhD, Senior Director, CMC, Apertura Gene Therapy

The Expert Speaker Faculty Includes:

Previously Attending Companies:

This summit is a meeting of the minds in vector biology and innovation and is a wonderful way to learn and explore novel ideas for more efficient and effective therapeutic development.

Roxanne Croze, Senior Director, Vector Innovation, 4D Molecular Therapeutics

Roxanne

Our 2025 Partners: